PDCD1 and Marinesco-Sjogren syndrome: Meanwhile, some of the ongoing trials for EC that are still recruiting are phase 2 NCT06415851 [75] and NCT05163483 [76], with the former evaluating the combination of bevacizumab, chemotherapy, and anti-PD-1 in patients with advanced EC [75], while the latter evaluates the combination of bevacizumab, anti-PD-1, and tucidinostat (HDAC inhibitor) for patients with advanced MSS/MMR EC [76].